Giant Health

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.

Previous post
Back to list
Next post